Abstract: The present disclosure relates to a power control method and apparatus, where the method includes: respectively determining, by a base station, error vector magnitude EVM indicator adjustment parameters of n terminals according to terminal types of the n terminals that are currently scheduled; processing, according to the EVM indicator adjustment parameters of the n terminals, to-be-transmitted signals of the n terminals to obtain an output signal, and determining a change of total power of the output signal relative to the to-be-transmitted signals; and dynamically controlling a supply voltage of a power amplifier according to the change of the total power of the output signal relative to the to-be-transmitted signals. According to the power control method and apparatus provided in embodiments of the present disclosure, different processing is performed on signals of different terminals, so that system performance of the OFDM system is improved.

Abstract: Embodiments of the present invention provide a method and a device for reducing intermodulation interference. The method includes: performing real-time estimation according to time domain information of M downlink transmit signals, to obtain a first intermodulation interference signal; and cancelling, according to the first intermodulation interference signal, intermodulation interference generated by the M downlink transmit signals in an uplink receive signal, where M is an integer greater than or equal to 2, and the M downlink transmit signals are baseband signals that are transmitted on M carriers and that are not combined. Based on the foregoing solutions, the actually generated intermodulation interference can be effectively cancelled, thereby reducing intermodulation interference and improving system performance.

Abstract: A nucleic acid sequence that exhibits prostate-specific expression and over-expression in tumor cells is disclosed. The sequence and fragments thereof are useful for detecting, diagnosing, preventing, and treating prostate cancer and other prostate related diseases. The sequence is also useful for measuring hormone responsiveness of prostate cancer cells.

Abstract: A nucleic acid sequence that exhibits prostate-specific expression and over-expression in tumor cells is disclosed. The sequence and fragments thereof are useful for detecting, diagnosing, preventing, and treating prostate cancer and other prostate related diseases. The sequence is also useful for measuring hormone responsiveness of prostate cancer cells.

Abstract: A nucleic acid sequence that exhibits prostate-specific expression and over-expression in tumor cells is disclosed. The sequence and fragments thereof are useful for detecting, diagnosing, preventing, and treating prostate cancer and other prostate related diseases. The sequence is also useful for measuring hormone responsiveness of prostate cancer cells.

Abstract: A nucleic acid sequence that exhibits prostate-specific expression and over-expression in tumor cells is disclosed. The sequence and fragments thereof are useful for detecting, diagnosing, preventing, and treating prostate cancer and other prostate related diseases. The sequence is also useful for measuring hormone responsiveness of prostate cancer cells.

Abstract: An isolated DNA encoding a polypeptide substantially identical to maspin (SEQ ID NO:1); a substantially purified preparation of maspin; an antibody specific for maspin; and use of such DNAs and antibodies in diagnostic, screening, and therapeutic methods.

Abstract: An isolated DNA encoding a polypeptide substantially identical to maspin (SEQ ID NO:1); a substantially purified preparation of maspin; an antibody specific for maspin; and use of such DNAs and antibodies in diagnostic, screening, and therapeutic methods.

Abstract: A method of determining whether a test cell from a given human tissue type is (a) normal, or (b) cancerous or precancerous, by contacting the mRNA of the test cell with a nucleic acid probe which contains a nucleotide sequence at least 15 nucleotides in length which is complementary to a portion of the coding sequence of a candidate tumor suppressor gene, which gene is one that is expressed at a given control level in normal cells of that tissue type; and determining the approximate amount of hybridization of the probe to the mRNA of the test cell, an amount of hybridization one-third or less that seen with the mRNA of a normal cell of that tissue type being an indication that the test cell is cancerous or precancerous. Alternatively, an antibody specific for the candidate tumor suppressor gene product can be substituted for the nucleic acid probe as a means for determining the level of expression of the gene in the test cell.

Abstract: An isolated DNA encoding a polypeptide substantially identical to maspin (SEQ ID NO:1); a substantially purified preparation of maspin; an antibody specific for maspin; and use of such DNAs and antibodies in diagnostic, screening, and therapeutic methods.